You are here: Industry Insights > Innovent

News List

Updated Overall Survival Data and Biomarker Results from Sintilimab ORIENT-11 Study in First-Line Nonsquamous Non-Small Cell Lung Cancer Published in the Journal of Thoracic Oncology prnasia
August 06, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, and Eli Lilly and Company today ...
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors prnasia
July 26, 2021
Innovent Biologics, Inc. today announced that the first patient has been dosed in a Phase 1 study of IBI321, an anti-PD-1/TIGIT bispecific antibody.
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI319 (Anti-PD-1/CD137 Bispecific Antibody) in Patients with Advanced Malignant Tumors prnasia
July 16, 2021
Innovent Biologics, Inc. announced that the first patient has been dosed in a Phase 1a/1b study of IBI319, an anti-PD-1/CD137 bispecific antibody.
Innovent and Ascentage Pharma Reach Multifaceted Strategic Agreement including Joint Commercialization of Olverembatinib in China, Joint Clinical Development on Multiple Products, and Equity Investmen prnasia
July 15, 2021
Innovent Biologics, Inc and Ascentage Pharma, announced a multifaceted strategic collaboration.
Ascentage Pharma and Innovent Biologics Reach Multifaceted Strategic Agreement Totaling US$245 Million Including Commercialization of Olverembatinib (HQP1351) in China, Joint Clinical Development of L prnasia
July 15, 2021
Ascentage Pharma, a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics, today announced a multifaceted strategic collaboration.
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI323 (Anti-LAG-3/PD-L1 Bispecific Antibody) in Patients with Advanced Malignant Tumors prnasia
July 12, 2021
Innovent Biologics, Inc. today announced that the first patient has been dosed in a Phase 1 study of IBI323, an anti-LAG-3/PD-L1 bispecific antibody.
Innovent Announces NMPA Acceptance of New Drug Application for the FGFR1/2/3 Inhibitor (Pemigatinib) for the Treatment of Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Ch prnasia
July 09, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases announced that the National Medical ...
Innovent and Laekna Therapeutics Enter a Partnership Agreement to Co-Develop Combination Therapy of Sintilimab and Afuresertib in Clinical Studies in China prnasia
July 06, 2021
Innovent and Laekna today jointly announced they have entered into a collaboration agreement to evaluate the combination of Innovent's PD-1 inhibitor sintilimab and Laekna's pan-AKT kinase inhibitor afuresertib.
Innovent Biologics Signs License Agreement with Synaffix contractpharma
July 02, 2021
Synaffix will provide proprietary ADC technologies to enable Innovent to rapidly progress one of its antibodies as a best-in-class ADC candidate.
Innovent Announces License Agreement with Synaffix in an ADC Technology Deal prnasia
June 29, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced the signing of ...

Previous page 1 2 3 4 5 6 7 8 9 Next page